NR4A1 and malignant colon neoplasm: The results show that piperlongumine decreased luciferase activity in RKO (Figure 1D), SW480 (Figure 1E), and HCT116 (Figure 1F) colon cancer cells demonstrating the NR4A1 inverse agonist activity of piperlongumine for this transactivation response.